United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $586.86 -1.01%
EPS Growth %: -13.3%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: -13.3%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $1.32, $0.39 better than the analyst estimate of $0.93. Revenue for the quarter came in at $204.2 million versus the consensus estimate of $203.91 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- UBS Reiterates Buy Rating on Bob's Discount Furniture (BOBS) on Long-Term Earnings Power
- Bloom Energy stock rises on analyst support and AI outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
